Compare · CNTB vs NVO
CNTB vs NVO
Side-by-side comparison of Connect Biopharma Holdings Limited (CNTB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNTB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 1486.9x CNTB ($149.9M).
- Over the past year, CNTB is up 37.4% and NVO is down 21.8% - CNTB leads by 59.1 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for CNTB).
- NVO has more recent analyst coverage (25 ratings vs 7 for CNTB).
- Company
- Connect Biopharma Holdings Limited
- Novo Nordisk A/S
- Price
- $2.39+2.14%
- $50.31-2.25%
- Market cap
- $149.9M
- $222.81B
- 1M return
- +19.50%
- +15.47%
- 1Y return
- +37.36%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 5
- Recent ratings
- 7
- 25
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CNTB
- Director Xanthopoulos Kleanthis Gabriel was granted 3,738 units of Ordinary Shares, increasing direct ownership by 5% to 86,554 units (SEC Form 4)
- Director Liu Jean I was granted 6,718 units of Ordinary Shares, increasing direct ownership by 133% to 11,779 units (SEC Form 4)
- Piper Sandler initiated coverage on Connect Biopharma with a new price target
- Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
- Director Huang James bought $371,610 worth of Ordinary Shares (150,000 units at $2.48) (SEC Form 4)
- SEC Form EFFECT filed by Connect Biopharma Holdings Limited
- Canaccord Genuity initiated coverage on Connect Biopharma with a new price target
- Cantor Fitzgerald initiated coverage on Connect Biopharma with a new price target
- SEC Form F-3 filed by Connect Biopharma Holdings Limited
- Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S